← All stocks

Protara Therapeutics, Inc.

TARA Net selling
CIK 0001359931 #3837 in the set updated 20 Sep 2026
Bought (12 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$1.01M
$0.00 on a plan · $882.16K straight out of an exercise
Sold at will
$124.99K
2 of 3 sales
Net
−$1.01M
−$124.99K against sales at will

By person

7 insiders · 3 transactions
4.3×

Jesse Shefferman holds only 4.3 times base salary in stock. $2.83M of shares against $654.89K in salary for 2025.

Salary from the company's own proxy. The shares are what Jesse Shefferman last reported holding, valued at $4.09, the price Common Stock was last bought or sold at on the open market here, on 29 Jun 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Shefferman Jesse
CEO and President
$882.16K (1) scheduled
−$882.16K
691,832
$2.83M
−26.0%
Zummo Jacqueline
Chief R&D Officer
$124.99K (2)
−$124.99K
94,827
$387.84K
−9.1%
Nicacio Leonardo Viana
Chief Medical Officer
78,181
$319.76K
+3,485%
CONKLING WILLIAM
Chief Commercial Officer
69,992
$286.27K
Fabbio Patrick
Chief Financial Officer
64,115
$262.23K
+191.4%
Levy Richard S
Director
51,000
$208.59K
+64.5%
Fry Hannah
VP, Controller
42,723
$174.74K
+43.2%

No percentages here. This company's share count has moved by a factor of 2.9 over the window, from 20,629,772 to 59,095,488 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
Zummo Jacqueline
8 Apr 2026
Chief R&D Officer
Sell
1,134
$5.40
$6.12K
Zummo Jacqueline
1 Apr 2026
Chief R&D Officer
Sell
22,598
$5.26
$118.87K

What was left out

Form 4 filings counted 26
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 1
Sales at will 2
Transactions with no price 0
Shares from compensation/vesting 503,464
History held since 1 Sep 2016